Patient and transplantation characteristics
| Characteristic . | Total (N = 937) . | Alive (n = 604) . | Died (n = 333) . |
|---|---|---|---|
| Median age at transplantation, y (range) | 52 (18-78) | 51 (18-77) | 54 (18-78) |
| Sex | |||
| Female | 377 (40) | 244 (40) | 133 (40) |
| Male | 560 (60) | 360 (60) | 200 (60) |
| Diagnosis | |||
| AML/ALL | 438 (47) | 282 (47) | 156 (47) |
| CML/CLL | 105 (11) | 66 (11) | 39 (12) |
| MDS/MPD | 158 (17) | 103 (17) | 55 (17) |
| NHL/HL | 149 (16) | 97 (16) | 52 (16) |
| Other | 87 (9) | 56 (9) | 31 (9) |
| Donor type | |||
| Matched related | 358 (38) | 236 (39) | 122 (37) |
| Matched unrelated | 436 (47) | 276 (46) | 160 (48) |
| Mismatched | 142 (15) | 91 (15) | 51 (15) |
| Missing | 1 | 1 | 0 |
| Graft source | |||
| Peripheral blood | 840 (90) | 536 (89) | 304 (91) |
| Bone marrow | 58 (6) | 42 (7) | 16 (5) |
| Cord blood | 37 (4) | 24 (4) | 13 (4) |
| Missing | 2 | 2 | 0 |
| Conditioning intensity | |||
| Myeloablative | 472 (51) | 326 (54) | 146 (44) |
| RIC/NMA | 461 (49) | 275 (46) | 186 (56) |
| Missing | 4 | 3 | 1 |
| Acute GVHD grades 2-4 | |||
| No | 462 (50) | 310 (52) | 152 (46) |
| Yes | 467 (50) | 287 (48) | 180 (54) |
| Missing | 8 | 7 | 1 |
| Relapse | |||
| No | 793 (85) | 567 (94) | 226 (68) |
| Yes | 144 (15) | 37 (6) | 107 (32) |
| Median year of transplantation (range) | 2010 (1987-2017) | 2010 (1987-2017) | 2009 (2005-2016) |
| Characteristic . | Total (N = 937) . | Alive (n = 604) . | Died (n = 333) . |
|---|---|---|---|
| Median age at transplantation, y (range) | 52 (18-78) | 51 (18-77) | 54 (18-78) |
| Sex | |||
| Female | 377 (40) | 244 (40) | 133 (40) |
| Male | 560 (60) | 360 (60) | 200 (60) |
| Diagnosis | |||
| AML/ALL | 438 (47) | 282 (47) | 156 (47) |
| CML/CLL | 105 (11) | 66 (11) | 39 (12) |
| MDS/MPD | 158 (17) | 103 (17) | 55 (17) |
| NHL/HL | 149 (16) | 97 (16) | 52 (16) |
| Other | 87 (9) | 56 (9) | 31 (9) |
| Donor type | |||
| Matched related | 358 (38) | 236 (39) | 122 (37) |
| Matched unrelated | 436 (47) | 276 (46) | 160 (48) |
| Mismatched | 142 (15) | 91 (15) | 51 (15) |
| Missing | 1 | 1 | 0 |
| Graft source | |||
| Peripheral blood | 840 (90) | 536 (89) | 304 (91) |
| Bone marrow | 58 (6) | 42 (7) | 16 (5) |
| Cord blood | 37 (4) | 24 (4) | 13 (4) |
| Missing | 2 | 2 | 0 |
| Conditioning intensity | |||
| Myeloablative | 472 (51) | 326 (54) | 146 (44) |
| RIC/NMA | 461 (49) | 275 (46) | 186 (56) |
| Missing | 4 | 3 | 1 |
| Acute GVHD grades 2-4 | |||
| No | 462 (50) | 310 (52) | 152 (46) |
| Yes | 467 (50) | 287 (48) | 180 (54) |
| Missing | 8 | 7 | 1 |
| Relapse | |||
| No | 793 (85) | 567 (94) | 226 (68) |
| Yes | 144 (15) | 37 (6) | 107 (32) |
| Median year of transplantation (range) | 2010 (1987-2017) | 2010 (1987-2017) | 2009 (2005-2016) |
All data are presented as n (%), unless otherwise specified.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma; NMA, non-myeloablative.